Indications

• Congestive Heart Failure (CHF) with Systolic Dysfunction (see Congestive Heart Failure, [[Congestive Heart Failure]])

---

Pharmacology

• Phosphodiesterase Type 3 Inhibitor (see Phosphodiesterase Type 3 Inhibitors, [[Phosphodiesterase Type 3 Inhibitors]]): inhibits cAMP degradation
  • Increased Myocardial Contractility
  • Decreased Pulmonary Vascular Resistance (PVR)
  • Vasodilation (Afterload Reduction)

Metabolism

• xxx

---

Administration

• xxxx

Dose Adjustment

• Hepatic:
• Renal:

---

Adverse Effects

Other Adverse Effects

• xxx
• xxx
• xxx

---

References

• xxxx